These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27217341)

  • 21. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
    Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sudden death related cardiomyopathies - Hypertrophic cardiomyopathy.
    Goff ZD; Calkins H
    Prog Cardiovasc Dis; 2019; 62(3):212-216. PubMed ID: 31004609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
    Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
    J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients.
    Monserrat L; Elliott PM; Gimeno JR; Sharma S; Penas-Lado M; McKenna WJ
    J Am Coll Cardiol; 2003 Sep; 42(5):873-9. PubMed ID: 12957435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation.
    Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Michels M; Bundgaard H; Ten Berg JM; Veselka J
    Europace; 2018 Sep; 20(FI2):f198-f203. PubMed ID: 29016960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of hypertrophic cardiomyopathy according to global, regional, and multi-layer longitudinal strain analysis, and prediction of sudden cardiac death.
    Vergé MP; Cochet H; Reynaud A; Morlon L; Peyrou J; Vincent C; Rooryck C; Ritter P; Lafitte S; Réant P
    Int J Cardiovasc Imaging; 2018 Jul; 34(7):1091-1098. PubMed ID: 29488042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy.
    Magrì D; Limongelli G; Re F; Agostoni P; Zachara E; Correale M; Mastromarino V; Santolamazza C; Casenghi M; Pacileo G; Valente F; Musumeci B; Maruotti A; Volpe M; Autore C
    Heart; 2016 Apr; 102(8):602-9. PubMed ID: 26849900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
    Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New strategies for assessing the risk of sudden cardiac death in hypertrophic cardiomyopathy].
    Jaworski K; Możeńska O; Kosior DA
    Pol Merkur Lekarski; 2016 Aug; 41(242):65-9. PubMed ID: 27591441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: An international multicenter study.
    Balaji S; DiLorenzo MP; Fish FA; Etheridge SP; Aziz PF; Russell MW; Tisma S; Pflaumer A; Sreeram N; Kubus P; Law IH; Kantoch MJ; Kertesz NJ; Strieper M; Erickson CC; Moore JP; Nakano SJ; Singh HR; Chang P; Cohen M; Fournier A; Ilina MV; Smith RT; Zimmerman F; Horndasch M; Li W; Batra A; Liberman L; Hamilton R; Janson CM; Sanatani S; Zeltser I; McDaniel G; Blaufox AD; Garnreiter JM; Katcoff H; Shah M
    Heart Rhythm; 2019 Oct; 16(10):1462-1467. PubMed ID: 31026510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines.
    Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y
    Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy.
    Konstantinou DM; Efthimiadis GK; Vassilikos V; Paraskevaidis S; Pagourelias E; Maron BJ; Karvounis H
    J Cardiovasc Med (Hagerstown); 2016 Jun; 17(6):433-9. PubMed ID: 26885981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator.
    Park YM
    Korean J Intern Med; 2023 Jan; 38(1):7-15. PubMed ID: 36353786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. QT prolongation and sudden cardiac death risk in hypertrophic cardiomyopathy.
    Patel SI; Ackerman MJ; Shamoun FE; Geske JB; Ommen SR; Love WT; Cha SS; Bos JM; Lester SJ
    Acta Cardiol; 2019 Feb; 74(1):53-58. PubMed ID: 29513133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy.
    Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L
    Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the relationship between the ambulatory electrocardiography-based micro T-wave alternans and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy.
    Özyılmaz S; Püşüroğlu H
    Anatol J Cardiol; 2018 Sep; 20(3):165-173. PubMed ID: 30152798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy.
    Norrish G; Ding T; Field E; McLeod K; Ilina M; Stuart G; Bhole V; Uzun O; Brown E; Daubeney PEF; Lota A; Linter K; Mathur S; Bharucha T; Kok KL; Adwani S; Jones CB; Reinhardt Z; Omar RZ; Kaski JP
    Europace; 2019 Oct; 21(10):1559-1565. PubMed ID: 31155643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy.
    Maurizi N; Tanini I; Olivotto I; Amendola E; Limongelli G; Losi MA; Allocca G; Perego GB; Pieragnoli P; Ricciardi G; De Filippo P; Ferrari P; Quarta G; Viani S; Rapacciuolo A; Bongiorni MG; Cecchi F
    Int J Cardiol; 2017 Mar; 231():115-119. PubMed ID: 28073660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.